Full Press Release Details
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer.
IDYA
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
Key Takeaway: IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
Price reaction · baseline $34.26 (2024-07-05 close) · 6 other IDYA headline(s) in the window, move may be shared
day 0 close
+15.3%
day 1
+12.7%
day 3 · peak
+15.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma